{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:14:49Z","timestamp":1790039689965,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Struct Funct Genomics"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s10969-011-9102-6","type":"journal-article","created":{"date-parts":[[2011,2,25]],"date-time":"2011-02-25T05:34:10Z","timestamp":1298612050000},"page":"63-76","source":"Crossref","is-referenced-by-count":20,"title":["Leveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomallei"],"prefix":"10.1007","volume":"12","author":[{"given":"Darren W.","family":"Begley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess T.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Abendroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney A.","family":"Burris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janhavi","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Myler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Staker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance J.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,26]]},"reference":[{"issue":"5","key":"9102_CR1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/187152609789105687","volume":"9","author":"PJ Myler","year":"2009","unstructured":"Myler PJ, Stacy R, Stewart L, Staker BL, Van Voorhis WC, Varani G, Buchko GW (2009) The Seattle Structural Genomics Center for Infectious Disease (SSGCID). Infect Disord Drug Targets 9(5):493\u2013506","journal-title":"Infect Disord Drug Targets"},{"key":"9102_CR2","doi-asserted-by":"crossref","unstructured":"Van Voorhis WC, Hol WG, Myler PJ, Stewart LJ (2009) The role of medical structural genomics in discovering new drugs for infectious diseases. PLoS Comput Biol 5(10):e1000530","DOI":"10.1371\/journal.pcbi.1000530"},{"issue":"15","key":"9102_CR3","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.1021\/jm900259h","volume":"52","author":"DR Davies","year":"2009","unstructured":"Davies DR, Mamat B, Magnusson OT et al (2009) Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem 52(15):4694\u20134715","journal-title":"J Med Chem"},{"issue":"2","key":"9102_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/jm0495778","volume":"48","author":"MJ Hartshorn","year":"2005","unstructured":"Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H (2005) Fragment-based lead discovery using X-ray crystallography. J Med Chem 48(2):403\u2013413","journal-title":"J Med Chem"},{"issue":"15","key":"9102_CR5","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1021\/jm900357y","volume":"52","author":"PA Brough","year":"2009","unstructured":"Brough PA, Barril X, Borgognoni J et al (2009) Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2, 3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 52(15):4794\u20134809","journal-title":"J Med Chem"},{"issue":"2","key":"9102_CR6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nbt1059","volume":"23","author":"GL Card","year":"2005","unstructured":"Card GL, Blasdel L, England BP et al (2005) A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23(2):201\u2013207","journal-title":"Nat Biotechnol"},{"issue":"11","key":"9102_CR7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2174\/138955707782331722","volume":"7","author":"CD Duarte","year":"2007","unstructured":"Duarte CD, Barreiro EJ, Fraga CA (2007) Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem 7(11):1108\u20131119","journal-title":"Mini Rev Med Chem"},{"issue":"14","key":"9102_CR8","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/jm0700316","volume":"50","author":"GM Makara","year":"2007","unstructured":"Makara GM (2007) On sampling of fragment space. J Med Chem 50(14):3214\u20133221","journal-title":"J Med Chem"},{"issue":"3","key":"9102_CR9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1021\/ci000403i","volume":"41","author":"MM Hann","year":"2001","unstructured":"Hann MM, Leach AR, Harper G (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41(3):856\u2013864","journal-title":"J Chem Inf Comput Sci"},{"issue":"8","key":"9102_CR10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nrd1467","volume":"3","author":"DC Rees","year":"2004","unstructured":"Rees DC, Congreve M, Murray CW, Carr R (2004) Fragment-based lead discovery. Nat Rev Drug Discov 3(8):660\u2013672","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"9102_CR11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14787210.4.3.445","volume":"4","author":"V Wuthiekanun","year":"2006","unstructured":"Wuthiekanun V, Peacock SJ (2006) Management of melioidosis. Expert Rev Anti Infect Ther 4(3):445\u2013455","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"9102_CR12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1586\/eri.10.4","volume":"8","author":"DM Estes","year":"2010","unstructured":"Estes DM, Dow SW, Schweizer HP, Torres AG (2010) Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther 8(3):325\u2013338","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"7","key":"9102_CR13","first-page":"499","volume":"9","author":"J Gilad","year":"2007","unstructured":"Gilad J, Harary I, Dushnitsky T, Schwartz D, Amsalem Y (2007) Burkholderia mallei and Burkholderia pseudomallei as bioterrorism agents: national aspects of emergency preparedness. Isr Med Assoc J 9(7):499\u2013503","journal-title":"Isr Med Assoc J"},{"key":"9102_CR14","unstructured":"Centers for Disease Control and Prevention (2000) Biological and chemical terrorism: strategic plan for preparedness and response. Recommendations of the CDC Strategic Planning Workgroup. MMWR Recomm Rep 49(RR-4):1\u201314"},{"issue":"30","key":"9102_CR15","doi-asserted-by":"crossref","first-page":"21573","DOI":"10.1074\/jbc.R700005200","volume":"282","author":"WN Hunter","year":"2007","unstructured":"Hunter WN (2007) The non-mevalonate pathway of isoprenoid precursor biosynthesis. J Biol Chem 282(30):21573\u201321577","journal-title":"J Biol Chem"},{"key":"9102_CR16","doi-asserted-by":"crossref","unstructured":"Rohmer M, Knani M, Simonin P, Sutter B, Sahm H (1993) Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. Biochem J 295(Pt 2):517\u2013524","DOI":"10.1042\/bj2950517"},{"issue":"12","key":"9102_CR17","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00018-004-3381-z","volume":"61","author":"W Eisenreich","year":"2004","unstructured":"Eisenreich W, Bacher A, Arigoni D, Rohdich F (2004) Biosynthesis of isoprenoids via the non-mevalonate pathway. Cell Mol Life Sci 61(12):1401\u20131426","journal-title":"Cell Mol Life Sci"},{"issue":"5433","key":"9102_CR18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1126\/science.285.5433.1573","volume":"285","author":"H Jomaa","year":"1999","unstructured":"Jomaa H, Wiesner J, Sanderbrand S et al (1999) Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science 285(5433):1573\u20131576","journal-title":"Science"},{"issue":"9349","key":"9102_CR19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(02)11860-5","volume":"360","author":"MA Missinou","year":"2002","unstructured":"Missinou MA, Borrmann S, Schindler A et al (2002) Fosmidomycin for malaria. Lancet 360(9349):1941\u20131942","journal-title":"Lancet"},{"key":"9102_CR20","doi-asserted-by":"crossref","unstructured":"Wiesner J, Borrmann S, Jomaa H (2003) Fosmidomycin for the treatment of malaria. Parasitol Res 90 Suppl 2:S71\u2013S76","DOI":"10.1007\/s00436-002-0770-9"},{"issue":"9","key":"9102_CR21","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1128\/AAC.46.9.2889-2894.2002","volume":"46","author":"J Wiesner","year":"2002","unstructured":"Wiesner J, Henschker D, Hutchinson DB, Beck E, Jomaa H (2002) In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob Agents Chemother 46(9):2889\u20132894","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"9102_CR22","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1128\/AEM.00030-08","volume":"74","author":"M Thongdee","year":"2008","unstructured":"Thongdee M, Gallagher LA, Schell M, Dharakul T, Songsivilai S, Manoil C (2008) Targeted mutagenesis of Burkholderia thailandensis and Burkholderia pseudomallei through natural transformation of PCR fragments. Appl Environ Microbiol 74(10):2985\u20132989","journal-title":"Appl Environ Microbiol"},{"issue":"12","key":"9102_CR23","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q","volume":"38","author":"M Mayer","year":"1999","unstructured":"Mayer M, Meyer B (1999) Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed 38(12):1784\u20131788","journal-title":"Angew Chem Int Ed"},{"issue":"10","key":"9102_CR24","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/chem.200500636","volume":"12","author":"B Becattini","year":"2006","unstructured":"Becattini B, Pellecchia M (2006) SAR by ILOEs: an NMR-based approach to reverse chemical genetics. Chemistry 12(10):2658\u20132662","journal-title":"Chemistry"},{"issue":"3","key":"9102_CR25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1747-0285.2010.01010.x","volume":"76","author":"DW Begley","year":"2010","unstructured":"Begley DW, Zheng S, Varani G (2010) Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping. Chem Biol Drug Des 76(3):218\u2013233","journal-title":"Chem Biol Drug Des"},{"issue":"6","key":"9102_CR26","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/BF02192855","volume":"2","author":"M Piotto","year":"1992","unstructured":"Piotto M, Saudek V, Sklenar V (1992) Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J Biomol NMR 2(6):661\u2013665","journal-title":"J Biomol NMR"},{"key":"9102_CR27","doi-asserted-by":"crossref","unstructured":"Otwinowski Z, Minor W, Charles W, Carter Jr (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276(Pt A):307\u2013326","DOI":"10.1016\/S0076-6879(97)76066-X"},{"issue":"6","key":"9102_CR28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1107\/S0021889893005588","volume":"26","author":"W Kabsch","year":"1993","unstructured":"Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Crystallogr 26(6):795\u2013800","journal-title":"J Appl Crystallogr"},{"issue":"Pt 3","key":"9102_CR29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53(Pt 3):240\u2013255","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"9102_CR30","unstructured":"CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50(Pt 5):760\u20133"},{"issue":"Pt 4","key":"9102_CR31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1107\/S0907444906005270","volume":"62","author":"J Painter","year":"2006","unstructured":"Painter J, Merritt EA (2006) Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr 62(Pt 4):439\u2013450","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"9102_CR32","doi-asserted-by":"crossref","unstructured":"Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126\u201332","DOI":"10.1107\/S0907444904019158"},{"issue":"Pt 1","key":"9102_CR33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1107\/S0907444909042073","volume":"66","author":"VB Chen","year":"2010","unstructured":"Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66(Pt 1):12\u201321","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"9102_CR34","unstructured":"Berman H, Henrick K, Nakamura H (2003) Announcing the worldwide Protein Data Bank ( www.wwpdb.org ). Nat Struct Biol 10(12):980"},{"key":"9102_CR35","doi-asserted-by":"crossref","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank ( www.pdb.org ). Nucleic Acids Res 28(1):235\u2013242","DOI":"10.1093\/nar\/28.1.235"},{"issue":"1","key":"9102_CR36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrd706","volume":"1","author":"TL Blundell","year":"2002","unstructured":"Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1(1):45\u201354","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"9102_CR37","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/80319","volume":"18","author":"VL Nienaber","year":"2000","unstructured":"Nienaber VL, Richardson PL, Klighofer V, Bouska JJ, Giranda VL, Greer J (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat Biotechnol 18(10):1105\u20131108","journal-title":"Nat Biotechnol"},{"key":"9102_CR38","doi-asserted-by":"crossref","unstructured":"Begley DW, Davies DR, Hartley R, Edwards TE, Staker BL, Van Voorhis WC, Myler PJ, Stewart L (2011) fragment screening of infectious disease targets in a structural genomics environment. Methods Enzymol 493 (in press)","DOI":"10.1016\/B978-0-12-381274-2.00021-2"},{"issue":"1","key":"9102_CR39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/jmbi.2001.5341","volume":"316","author":"S Steinbacher","year":"2002","unstructured":"Steinbacher S, Kaiser J, Wungsintaweekul J, Hecht S, Eisenreich W, Gerhardt S, Bacher A, Rohdich F (2002) Structure of 2C-methyl-d-erythritol-2, 4-cyclodiphosphate synthase involved in mevalonate-independent biosynthesis of isoprenoids. J Mol Biol 316(1):79\u201388","journal-title":"J Mol Biol"},{"issue":"16","key":"9102_CR40","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.2174\/156802607782341109","volume":"7","author":"RE Hubbard","year":"2007","unstructured":"Hubbard RE, Davis B, Chen I, Drysdale MJ (2007) The SeeDs approach: integrating fragments into drug discovery. Curr Top Med Chem 7(16):1568\u20131581","journal-title":"Curr Top Med Chem"},{"issue":"6","key":"9102_CR41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14728222.8.6.597","volume":"8","author":"M Pellecchia","year":"2004","unstructured":"Pellecchia M, Becattini B, Crowell KJ, Fattorusso R, Forino M, Fragai M, Jung D, Mustelin T, Tautz L (2004) NMR-based techniques in the hit identification and optimisation processes. Expert Opin Ther Targets 8(6):597\u2013611","journal-title":"Expert Opin Ther Targets"},{"key":"9102_CR42","doi-asserted-by":"crossref","unstructured":"Zartler E, Shapiro M (2008) Fragment-based drug discovery: a practical approach. Wiley, Hoboken","DOI":"10.1002\/9780470721551"},{"issue":"1","key":"9102_CR43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1008360208627","volume":"15","author":"D Li","year":"1999","unstructured":"Li D, DeRose EF, London RE (1999) The inter-ligand Overhauser effect: a powerful new NMR approach for mapping structural relationships of macromolecular ligands. J Biomol NMR 15(1):71\u201376","journal-title":"J Biomol NMR"},{"key":"9102_CR44","doi-asserted-by":"crossref","unstructured":"Davies DR, Begley DW, Hartley R, Staker BL, Stewart L (2011) Predicting success in fragment screening by X-ray crystallography. Methods Enzymol 493 (in press)","DOI":"10.1016\/B978-0-12-381274-2.00004-2"},{"issue":"5","key":"9102_CR45","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1747-0285.2008.00648.x","volume":"71","author":"J Liu","year":"2008","unstructured":"Liu J, Begley D, Mitchell DD, Verlinde CL, Varani G, Fan E (2008) Multivalent drug design and inhibition of cholera toxin by specific and transient protein-ligand interactions. Chem Biol Drug Des 71(5):408\u2013419","journal-title":"Chem Biol Drug Des"},{"issue":"8","key":"9102_CR46","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1021\/cr030409h","volume":"104","author":"CA Lepre","year":"2004","unstructured":"Lepre CA, Moore JM, Peng JW (2004) Theory and applications of NMR-based screening in pharmaceutical research. Chem Rev 104(8):3641\u20133676","journal-title":"Chem Rev"},{"issue":"8","key":"9102_CR47","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/anie.200390233","volume":"42","author":"B Meyer","year":"2003","unstructured":"Meyer B, Peters T (2003) NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew Chem Int Ed Engl 42(8):864\u2013890","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"9102_CR48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nbt.1598","volume":"28","author":"AB Burgin","year":"2010","unstructured":"Burgin AB, Magnusson OT, Singh J et al (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 28(1):63\u201370","journal-title":"Nat Biotechnol"},{"issue":"5","key":"9102_CR49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/cb700025j","volume":"2","author":"J Chen","year":"2007","unstructured":"Chen J, Zhang Z, Stebbins JL, Zhang X, Hoffman R, Moore A, Pellecchia M (2007) A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors. ACS Chem Biol 2(5):329\u2013336","journal-title":"ACS Chem Biol"},{"issue":"7042","key":"9102_CR50","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR et al (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435(7042):677\u2013681","journal-title":"Nature"},{"issue":"5292","key":"9102_CR51","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1126\/science.274.5292.1531","volume":"274","author":"SB Shuker","year":"1996","unstructured":"Shuker SB, Hajduk PJ, Meadows RP, Fesik SW (1996) Discovering high-affinity ligands for proteins: SAR by NMR. Science 274(5292):1531\u20131534","journal-title":"Science"},{"issue":"26","key":"9102_CR52","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1021\/jm0707424","volume":"50","author":"JL Stebbins","year":"2007","unstructured":"Stebbins JL, Zhang Z, Chen J, Wu B, Emdadi A, Williams ME, Cashman J, Pellecchia M (2007) Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors. J Med Chem 50(26):6607\u20136617","journal-title":"J Med Chem"},{"issue":"3","key":"9102_CR53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrd2220","volume":"6","author":"PJ Hajduk","year":"2007","unstructured":"Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6(3):211\u2013219","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"9102_CR54","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.cbpa.2005.05.002","volume":"9","author":"ER Zartler","year":"2005","unstructured":"Zartler ER, Shapiro MJ (2005) Fragonomics: fragment-based drug discovery. Curr Opin Chem Biol 9(4):366\u2013370","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"9102_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1\u201312","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9102_CR56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","volume":"6","author":"DJ Payne","year":"2007","unstructured":"Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6(1):29\u201340","journal-title":"Nat Rev Drug Discov"},{"key":"9102_CR57","volume-title":"The PyMOL Molecular Graphics System","author":"WL DeLano","year":"2008","unstructured":"DeLano WL (2008) The PyMOL Molecular Graphics System. DeLano Scientific LLC, Palo Alto"}],"container-title":["Journal of Structural and Functional Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10969-011-9102-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T14:34:24Z","timestamp":1712241264000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10969-011-9102-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,26]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["9102"],"URL":"https:\/\/doi.org\/10.1007\/s10969-011-9102-6","relation":{},"ISSN":["1345-711X","1570-0267"],"issn-type":[{"value":"1345-711X","type":"print"},{"value":"1570-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,26]]}}}